Novel Small Molecule Inhibitors for the Treatment of Huntington’s Disease


This technology is a collection of small molecules screened for their ability to prevent or reduce the cytotoxic effects of the protein, Huntingtin. Huntington's disease is a neurodegenerative disorder due to a dominantly acting expansion of a CAG trinucleotide repeat in exon 1 of the Huntington (HTT) gene resulting in production of the altered (mutant) protein Huntingtin, which has a long chain of polyglutamine (poly Q) attached to the exon 1 encoded protein sequence. Clinical and statistical analyses have shown that an increased number of poly Q repetition correlates with the probability of developing the disease, with 36 to 40 being the accepted cut off number for developing the disorder with high probability. It is known that poly Q repetitions impact the physical properties of Huntingtin and cause it to produce aggregates that precipitate and form inclusion bodies, which are toxic to the neuronal cells. The compounds of this invention have been screened multiply in a neuronal cell model of Huntington’s disease containing an HTT with an expanded repeat in exon 1 of 103 Qs for their ability to inhibit cytotoxicity and protein aggregation.

Potential Commercial Applications: Competitive Advantages:
Treatment of Huntington’s disease. 


Development Stage:
Early development.

Inventors:

Juan Marugan (NCATS)  ➽ more inventions...

Joshua McCoy (NCATS)  ➽ more inventions...

Samarjit Patnaik (NCATS)  ➽ more inventions...

Steven Titus (NCATS)  ➽ more inventions...

Wei Zheng (NCATS)  ➽ more inventions...

Noel Southall (NCATS)  ➽ more inventions...

Wenwei Huang (NCATS)  ➽ more inventions...


Intellectual Property:
US Application No. 61/388,482
PCT Application No. PCT/US2011/54325

Publications:
None

Collaboration Opportunity:

The National Center for Translational Therapeutics is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology further. Please contact Ms. Lili Portilla at Lilip@nih.gov for more information.


Licensing Contact:
Suryanarayana Vepa, Ph.D.
Email: sury.vepa@nih.gov
Phone: 301-217-9197

OTT Reference No: E-258-2010/0
Updated: Jun 8, 2011